FDA approves first generic versions of Cymbalta

The Food and Drug Administration says it has approved the first generic versions of the blockbuster antidepressant drug Cymbalta, offering lower-cost access to one of the most widely prescribed treatments for depression, anxiety and other disorders.

Cymbalta is Eli Lilly & Co. Inc.'s best-selling drug and posted 2012 sales of $4.7 billion, making it the fifth-highest selling medication worldwide. The drug's patent expired Thursday, clearing the way for the launch of cheaper versions of the drug from generic drugmakers.

Besides depression, Cymbalta is also prescribed to treat generalized anxiety disorder, diabetic nerve pain, fibromyalgia and forms of chronic pain.

The FDA said it approved six of the pill from generic drugmakers including Dr. Reddy's Laboratories Ltd., Sun Pharma Global and Teva Pharmaceuticals.


Explore further

Generic aciphex approved to treat chronic heartburn

© 2013 The Associated Press. All rights reserved.

Citation: FDA approves first generic versions of Cymbalta (2013, December 11) retrieved 15 September 2019 from https://medicalxpress.com/news/2013-12-fda-versions-cymbalta.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more